Female Health Company (The) (NASDAQ: VERU) is one of 113 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Female Health Company (The) to related businesses based on the strength of its valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Insider and Institutional Ownership

5.0% of Female Health Company (The) shares are owned by institutional investors. Comparatively, 43.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 10.9% of Female Health Company (The) shares are owned by company insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Female Health Company (The) and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Female Health Company (The) 0 0 2 0 3.00
Female Health Company (The) Competitors 790 3410 5862 137 2.52

Female Health Company (The) currently has a consensus price target of $5.00, indicating a potential upside of 141.55%. As a group, “Pharmaceuticals” companies have a potential upside of 21.82%. Given Female Health Company (The)’s stronger consensus rating and higher possible upside, analysts plainly believe Female Health Company (The) is more favorable than its competitors.

Earnings & Valuation

This table compares Female Health Company (The) and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Female Health Company (The) N/A N/A -10.89
Female Health Company (The) Competitors $7.79 billion $2.46 billion -0.15

Female Health Company (The)’s competitors have higher revenue and earnings than Female Health Company (The). Female Health Company (The) is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Female Health Company (The) and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Female Health Company (The) -42.02% -16.78% -10.64%
Female Health Company (The) Competitors -3,192.19% -54.63% -8.13%

Volatility & Risk

Female Health Company (The) has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Female Health Company (The)’s competitors have a beta of 0.87, suggesting that their average stock price is 13% less volatile than the S&P 500.

Summary

Female Health Company (The) beats its competitors on 6 of the 11 factors compared.

About Female Health Company (The)

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women’s Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.